Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Ublituximab (Primary) ; Ibrutinib
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GENUINE
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 12 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Nov 2019.
    • 12 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 11 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top